GEN

Genesis Healthcare (GEN)

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:GEN
DataOraFonteTitoloSimboloCompagnia
24/01/202312:27GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2022NYSE:GENGenesis Healthcare Inc
11/11/202202:49TipRanksRBC Capital Keeps Their Hold Rating on Gen Digital (GEN)NYSE:GENGenesis Healthcare Inc
09/11/202217:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2022NYSE:GENGenesis Healthcare Inc
03/11/202217:45GlobeNewswire Inc.Genmab Improves Its 2022 Financial GuidanceNYSE:GENGenesis Healthcare Inc
18/10/202212:35GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2022NYSE:GENGenesis Healthcare Inc
05/10/202221:56GlobeNewswire Inc.Major Shareholder AnnouncementNYSE:GENGenesis Healthcare Inc
10/08/202217:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2022NYSE:GENGenesis Healthcare Inc
19/07/202212:33GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2022NYSE:GENGenesis Healthcare Inc
18/07/202216:01GlobeNewswire Inc.Genmab Announces That AbbVie Will Submit Marketing Authorization Application to European Medicines Agency for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)NYSE:GENGenesis Healthcare Inc
30/06/202220:24GlobeNewswire Inc.Genmab to Submit Biologics License Application to U.S. Food and Drug Administration for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
09/06/202223:17GlobeNewswire Inc.Genmab Commences New Arbitration Under License Agreement With JanssenNYSE:GENGenesis Healthcare Inc
11/05/202217:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2022NYSE:GENGenesis Healthcare Inc
19/04/202212:29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2022NYSE:GENGenesis Healthcare Inc
13/04/202223:25GlobeNewswire Inc.Genmab and AbbVie Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) From Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)NYSE:GENGenesis Healthcare Inc
08/04/202201:44GlobeNewswire Inc.Genmab Announces the Initial Resolution of its Arbitration with Janssen Relating to their Daratumumab License AgreementNYSE:GENGenesis Healthcare Inc
24/02/202212:01GlobeNewswire Inc.Notice to Convene the Annual General Meeting of Genmab A/SNYSE:GENGenesis Healthcare Inc
16/02/202217:00GlobeNewswire Inc.Genmab Publishes 2021 Annual ReportNYSE:GENGenesis Healthcare Inc
25/01/202212:30GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for 2021NYSE:GENGenesis Healthcare Inc
04/01/202215:00GlobeNewswire Inc.Genmab and Synaffix Enter into License Agreement for ADC TechnologyNYSE:GENGenesis Healthcare Inc
10/11/202117:00GlobeNewswire Inc.Genmab Announces Financial Results for the First Nine Months of 2021NYSE:GENGenesis Healthcare Inc
04/11/202121:24GlobeNewswire Inc.Genmab Improves its 2021 Financial GuidanceNYSE:GENGenesis Healthcare Inc
19/10/202112:29GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Third Quarter of 2021NYSE:GENGenesis Healthcare Inc
21/09/202120:22GlobeNewswire Inc.Capital Increase in Genmab as a Result of Employee Warrant ExerciseNYSE:GENGenesis Healthcare Inc
20/09/202123:00GlobeNewswire Inc.Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK™ (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical CancerNYSE:GENGenesis Healthcare Inc
11/08/202117:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Half of 2021NYSE:GENGenesis Healthcare Inc
21/07/202112:31GlobeNewswire Inc.Genmab Announces Net Sales of DARZALEX® (daratumumab) for the Second Quarter of 2021NYSE:GENGenesis Healthcare Inc
22/06/202116:12GlobeNewswire Inc.Genmab Announces that Janssen has Received European Marketing Authorizations for DARZALEX® (daratumumab) Subcutaneous Formul...NYSE:GENGenesis Healthcare Inc
28/05/202122:30Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NYSE:GENGenesis Healthcare Inc
21/05/202115:08GlobeNewswire Inc.Genmab Announces that Janssen has Received Positive CHMP Opinion Recommending DARZALEX® (daratumumab) Subcutaneous (SC) Form...NYSE:GENGenesis Healthcare Inc
05/05/202117:01GlobeNewswire Inc.Genmab Announces Financial Results for the First Quarter of 2021NYSE:GENGenesis Healthcare Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NYSE:GEN
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network